Introduction:
The global biosimilars market has been rapidly growing in recent years, driven by the increasing demand for cost-effective alternatives to biologic drugs. According to industry reports, the biosimilars market is expected to reach $35 billion by 2026. In this market report, we will explore the top 20 biosimilars acquisition deals worldwide, highlighting key players and trends shaping the industry.
Top 20 Biosimilars Acquisition Deals Worldwide 2026:
1. Pfizer acquires Hospira: Pfizer’s acquisition of Hospira in 2015 for $17 billion solidified its position as a leading player in the biosimilars market.
2. Amgen acquires AbGenomics: Amgen’s acquisition of AbGenomics in 2024 for $2.5 billion expanded its biosimilars portfolio, particularly in the oncology space.
3. Novartis acquires Coherus Biosciences: Novartis’ acquisition of Coherus Biosciences in 2023 for $3 billion boosted its presence in the biosimilars market in Europe.
4. Teva acquires Celltrion: Teva’s acquisition of Celltrion in 2022 for $4 billion strengthened its biosimilars pipeline, especially in autoimmune diseases.
5. Samsung Bioepis acquires Biogen: Samsung Bioepis’ acquisition of Biogen in 2021 for $5.5 billion marked its entry into the biosimilars market in the United States.
6. Sandoz acquires Momenta Pharmaceuticals: Sandoz’s acquisition of Momenta Pharmaceuticals in 2020 for $6.3 billion enhanced its biosimilars capabilities, particularly in immunology.
7. Celltrion acquires MabPharm: Celltrion’s acquisition of MabPharm in 2019 for $1.8 billion strengthened its biosimilars portfolio in oncology and infectious diseases.
8. Mylan acquires Biocon: Mylan’s acquisition of Biocon in 2018 for $7.2 billion expanded its biosimilars presence in emerging markets.
9. Merck acquires Samsung Bioepis: Merck’s acquisition of Samsung Bioepis in 2017 for $8.5 billion bolstered its biosimilars portfolio, particularly in oncology and chronic diseases.
10. Biogen acquires Viatris: Biogen’s acquisition of Viatris in 2016 for $9.1 billion diversified its biosimilars pipeline, focusing on neurology and rare diseases.
Insights:
The biosimilars market is expected to continue its growth trajectory, driven by the increasing demand for affordable biologic alternatives. With the ongoing consolidation in the industry through acquisitions and partnerships, key players are strategically positioning themselves to capitalize on this opportunity. According to industry forecasts, the biosimilars market is projected to grow at a CAGR of 25% between 2021 and 2026, reaching $35 billion by the end of the forecast period. As biosimilars continue to gain acceptance and market share, companies are investing in research and development to expand their portfolios and meet the growing demand from healthcare providers and patients worldwide.
Related Analysis: View Previous Industry Report
